Zenith Drugs Return on Equity (ROE) History

Zenith Drugs Ltd Return on Equity

The Zenith Drugs Ltd Return on Equity is a key financial metric used by investors to evaluate Zenith Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Zenith Drugs Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Zenith Drugs Ltd (NSE: ZENITHDRUG, BSE: 92356) is currently trading at ₹39.95, with a market capitalization of ₹653.37M. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Zenith Drugs Ltd Return on Equity is essential for fundamental analysis.

Zenith Drugs Ltd Return on Equity Current Value

The current Zenith Drugs Ltd Return on Equity stands at 10.88.

The Zenith Drugs Ltd Return on Equity has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.

Zenith Drugs Ltd Return on Equity Historical Trend

The Zenith Drugs Ltd Return on Equity has shown the following historical trend:

• 2024: 10.88
• 2023: 24
• 2022: 35.13
• 2021: 29.83
• 2020: 0

The decline in Zenith Drugs Ltd Return on Equity indicates improving financial efficiency or better earnings growth.

What Zenith Drugs Ltd Return on Equity Indicates for Investors

The Zenith Drugs Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.

ROE indicates how efficiently the company generates returns for shareholders.

Zenith Drugs Ltd Return on Equity Analysis Summary

The Zenith Drugs Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Zenith Drugs Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Zenith Drugs Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.